Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Pulse Biosciences, Inc Common Stock (DE)

PLSE

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.

Last trade $43.82
Day change -$2.54 (-5.48%)
Day range $43.32 – $46.64
Volume 320,463
Market cap $3.41B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$3.41B
Price / earnings
—
Price / book
18.57×
Price / sales
2,282.28×
EV / sales
2,257.7×
EV / EBITDA
-39.25×

Profitability

Earnings per share
-$1.14
Return on assets
-41.53%
Return on equity
-45.61%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
14.35×
Quick ratio
14.33×
Cash ratio
2.74×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$63.7M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PLSE, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$395K$434K$401K$264K$86K$0$0$0
Cost of revenue$191K$273K$370K$260K$279K$0$0$0
Gross profit$204K$161K$31K$4K-$193K$0$0$0
Selling, general and administrative$7.65M$8.46M$6.59M$7.33M$8.78M$8.19M$7.73M$9.6M
Research and development$16.85M$16.98M$12.59M$10.93M$11.39M$12.09M$10.31M$10.66M
Total operating expenses$24.5M$25.43M$19.18M$18.26M$20.17M$20.28M$18.04M$20.26M
Operating income-$24.29M-$25.27M-$19.15M-$18.25M-$20.37M-$20.28M-$18.04M-$20.26M
Interest expense$1.21M$600K$593K$0$1M$1.13M$1.26M$0
Income before taxes-$23.05M-$24.66M-$18.58M-$17.43M-$19.39M-$19.17M-$16.8M-$19.39M
Income taxes$0$0$0$0$0$0$0$0
Net income-$23.05M-$24.66M-$18.58M-$17.43M-$19.39M-$19.17M-$16.8M-$19.39M
Net income attributable to common shareholders-$23.05M-$24.66M-$18.58M-$17.43M-$19.39M-$19.17M-$16.8M-$19.39M
EBITDA-$24.03M-$25.02M-$18.9M-$17.99M-$20.11M-$20M-$17.76M-$19.97M
Basic earnings per share-$0.32-$0.36-$0.27-$0.26-$0.29-$0.28-$0.25-$0.33
Diluted earnings per share-$0.32-$0.36-$0.27-$0.26-$0.29-$0.28-$0.25-$0.33

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Pulse Biosciences, Inc (PLSE) Reports Q3 Loss, Misses Revenue Estimates

Pulse Biosciences reported a Q3 loss of $0.32 per share, beating EPS estimates but missing revenue expectations with $0.4 million versus consensus estimates. The company has significantly outperformed the S&P 500 this year with a 315.6% gain. The stock holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

Zacks Investment Research

Si-Bone (SIBN) Reports Q3 Loss, Tops Revenue Estimates

Si-Bone (SIBN) reported a quarterly loss of $0.08 per share, beating the consensus estimate of $0.13 loss by 38.46%, with revenues of $55.7 million slightly exceeding expectations. The company has surpassed consensus estimates four times over the last four quarters. However, shares have underperformed the S&P 500 year-to-date, gaining 7.7% versus the market's 10.7%. The stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.

The Motley Fool

Pulse Biosciences (PLSE) Q1 2025 Earnings Transcript

Pulse Biosciences reported Q1 2025 results showing increased operating expenses and net losses as the company expanded its organization and advanced clinical studies. The company demonstrated progress across three product areas: the soft tissue ablation device for benign thyroid nodules (90+ patients treated in pilot program), the 360 cardiac catheter system (100 patients treated in European feasibility study with 94.2% remapping success rate), and the cardiac surgical clamp (30 patients treated with FDA breakthrough designation). Cash position strengthened to $119.3 million, supported by $14.1 million in warrant exercise proceeds. The company expects to initiate commercialization of the thyroid nodule device in H2 2025 and commence IDE pivotal studies for cardiac devices by mid-year.

Benzinga

Oxford Industries, PVH And 3 Stocks To Watch Heading Into Monday

With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: Wall Street expects PVH Corp. (NYSE: PVH) to report quarterly earnings at $3.52 per share on revenue of $2.42 billion after the closing bell, according to data from Benzinga Pro. PVH shares gained 0.3% to $141.00 in after-hours trading. Oxford Industries, Inc. (NYSE: OXM) reported downbeat financial results ...

Benzinga

Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Shares of Mesoblast Limited (NASDAQ: MESO) rose sharply during Monday’s session after the company announced FDA support of an accelerated approval pathway for rexlemestrocel-L in end-stage heart failure patients. Mesoblast shares jumped 13.4% to $2.4399 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Kidpik Corp. (NASDAQ: PIK) gained 238% to $9.15. Kidpik recently announced a 1-for 5 reverse stock split. TC Biopharm (Holdings) Plc (NASDAQ: TCBP) shares surged 149% to $2.6450. TRxADE HEALTH, Inc. (NASDAQ: MEDS) gained 114.6% to $17.26. TRxADE Health recently announced a special cash dividend of $8 per share. Fangdd Network Group Ltd. (NASDAQ: DUO) shares climbed 108% to $1.2593 after the company announced its 2024 strategic layout with plans to enter the real estate stock asset services sector. GDS Holdings Limited (NASDAQ: GDS) shares gained 23.7% to $7.93 following a report suggesting Hillhouse and Boyu are in talks to invest in the company's Southeast Asia data center business. Solidion Technology Inc. (NASDAQ: STI) rose 23.3% to $0.9620. Kingsoft Cloud Holdings Limited (NASDAQ: KC) shares gained 23.1% to $3.31. Kingsoft Cloud is expected to report fourth-quarter financial results on March 20, 2024. EHang Holdings Limited (NASDAQ: EH) gained 21.7% to $13.89. EHang Holdings is expected to release its unaudited financial results for the fourth quarter on March 15, 2024. Bally's Corporation (NYSE: BALY) gained 21.5% to $12.90. Standard General delivered a non-binding letter to the board of directors of Bally's proposing a transaction under which it would acquire all of the outstanding shares of common stock for $15/share, not currently owned by the company. Rail Vision Ltd. (NASDAQ: RVSN) climbed 21.2% to $3.43. Rail Vision ...

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.